A Phase 4 interventional study of Clopidogrel (Plavix) Pharmacogenetic Test Reagents in Peripheral Arterial Disease, sponsored by Corewell Health West. Recruiting at 2 sites in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Corewell Health West · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing clopidogrel in Peripheral Arterial Disease — 3 open to participants now, 4 under way, none of them phase 3. Clopidogrel · Peripheral Arterial Disease.
Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 4, and was the 8th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →3 of the 10 studies testing clopidogrel in Peripheral Arterial Disease are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 205 across the 10 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 8 most frequent:
Corewell Health West is the lead sponsor of 16 studies on the registry; 9 are open to participants now.
Corewell Health West has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
2 of the studies testing clopidogrel in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
| NCT07076082Corewell Health WestVascular Trial Associated Registry Pilot | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
The Main Objective of this study is to create an investigator-initiated, multicenter, open label, randomized trial to evaluate 1 month vs. 6 months of DAPT in patients undergoing lower extremity endovascular revascularization. The randomization will be 1:1 within one strata (diabetes yes/no), using blocks of varying sizes. All patients will be on DAPT for one month. At the time of the one-month visit, eligible patients who consent will be randomized to single antiplatelet therapy (SAPT) indefinitely (Arm 1) or to DAPT for 5 more months (followed by SAPT) (Arm 2). Follow-up will continue for 12-months post-procedure and will include assessment of MACE and MALE, as well as adverse bleeding events. Data for this trial will be collected via nested participation in the VQI Peripheral Vascular Intervention (PVI) registry's existing Procedural and Follow-up data collection modules.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with high bleeding risk (HBR) defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
Drug: Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Aspirin and Clopidogrel (Plavix) for 6-months post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
Drug: Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
The proportion of patients eligible who are offered study enrollment
Patients who undergo PVI that meet inclusion criteria and are offered enrollment.
Time frame: 1 year
The proportion of eligible patients who consent to enrollment and randomization
Patients who meet inclusion criteria and agree to participate in trial vs those that do not agree to participate in trial
Time frame: 1 year
The proportion of enrolled patients who have the primary (composite) event of interest defined at 6 months
The number of enrolled patients that have the occurrence of one of the following stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.
Time frame: 6-months
The proportion of enrolled patients who have the primary (composite) event of interest defined at 12 months
The number of enrolled patients that have the occurrence of one of the following stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.
Time frame: 1 year
The numbers and proportions of patients who have each type of major event
Of the enrolled patients that have a medical primary event how many individuals were in each category stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.
Time frame: 1 year
The proportions of patients who have major event status recorded at each observation time
Major event status at 1, 6-months post PVI and 12-month post PVI
Time frame: 1 year
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 28 phase 4 interventional studies under Peripheral Arterial Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel
Corewell Health West